Loading...
•
Jun 30, 2023
Intra-Cellular Q2 2023 Earnings Report
Intra-Cellular Therapies experienced revenue growth driven by CAPLYTA sales and raised full year net product sales guidance.
Key Takeaways
Intra-Cellular Therapies reported a strong second quarter in 2023, with total revenues increasing to $110.8 million, driven by a 100% increase in CAPLYTA net product sales compared to the same period in 2022. The company raised its full year 2023 CAPLYTA net product sales guidance to $445 to $465 million.
Total revenues for Q2 2023 increased to $110.8 million, compared to $55.6 million in Q2 2022.
CAPLYTA net product sales for Q2 2023 were $110.1 million, a 100% increase compared to $55.1 million in Q2 2022.
CAPLYTA total prescriptions increased 96% versus the same period in 2022.
Full year 2023 CAPLYTA net product sales guidance was raised to $445 - $465 million.
Forward Guidance
Intra-Cellular Therapies increased full year 2023 CAPLYTA net product sales guidance to $445 to $465 million and reiterated SG&A expense guidance of $420 to $450 million and R&D expense guidance of $195 to $220 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...